Supplementary Material

Content:

Supplementary Table 1

Supplementary Table 2

Supplementary Table 3

Supplementary Table 4

Supplementary Figure 1

Supplementary Figure 2

Supplementary Table 1. Definition of tuberculosis treatment outcomes

Type of outcome treatment	Outcome tuberculosis treatment	RePORT	SINAN ^a
Favorable	Cure	Resolution of symptoms consistent with TB by the end of therapy. Patients without symptoms consistent with TB at the beginning of TB treatment could not have their clinical response evaluated.	Cure is established when pulmonary TB patients, initially sputum smear-positive, present, during treatment, with at least two negative sputum smears: one in the follow-up phase and the other at the end of treatment.
	Completed treatment	When the patient does not have treatment failure or loss to follow-up and has received at least 90% of the total number of doses of the standard recommended anti-TB therapy by the National TB Program for a period of up to one year for drug susceptible cases, and up to two years for MDR cases. For drug-susceptible TB, the drug regimen consisted of isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampin for 4 months. For drug-resistant TB, treatment was based on drug susceptibility test results.	Completion of treatment based on clinical criteria and radiological: (i) when the patient has not undergone sputum examination due to absence sputum and are discharged based on clinical data and complementary exams, (ii) in cases of initially negative pulmonary tuberculosis; (iii) in cases of extrapulmonary tuberculosis
Unfavorable	Treatment modification	Switch to second line treatment ^b	When there is confirmation, through sensitivity testing or molecular rapid testing for tuberculosis, of resistance to any anti-tuberculosis medication, regardless of the treatment regimen treatment to be used, except in cases of monoresistance to ethambutol, pyrazinamide or streptomycin that keep using the basic regimen.
	Failure	Sputum smear- or culture-positive at month 5 or later during treatment.	When sputum positivity persists at the end treatment. Also classified as failure are patients who beginning of treatment are strongly positive (++ or +++) and maintain this until the fourth month, or those with initial positivity followed by negativity and new positivity for two consecutive months, from the fourth month of treatment.
	Death	A participant who dies for any reason after consenting to participate and prior to the end of the study.	On the occasion of knowledge of the patient's death during treatment.
	Recurrence	(i) Clinical or radiological evidence of active tuberculosis after completion of therapy (during the follow-up period) and met the definition for clinical cure, bacteriologic cure or	Relapse cases are not reported as treatment outcomes to SINAN.

	bacteriologic status indeterminate with treatment complete. This includes persons who are AFB smear-positive or Xpert MTB/RIF-positive but AFB culture- negative. (ii) Positive culture for <i>M. tuberculosis</i> in liquid or solid medium (with any colony count), among patients who did not experience treatment failure and were considered "cured" or "bacteriologic status indeterminate with treatment completed", in a clinical sample collected after the end of the treatment, during the follow-up phase.	
Transferred out	When the patient is transferred to another health service.	When the patient is transferred to another health service.
Loss to follow-up	A participant who no longer participates in study visit follow- up or when an outcome cannot be assigned due to insufficient information.	A patient who has failed to attend the unit for more than 30 consecutive days after the expected return date. In treatment cases supervised, the period of 30 days is counted from the last date of taking the drug.

Table note: ^aDescribed in the Manual of Recommendations for the Control of TB of Brazil. Abbreviations: RePORT: Regional Prospective Observational Research for Tuberculosis. SINAN: Sistema de Informação de Agravos de Notificação. MDR: Multidrug-Resistant. TB: Tuberculosis. ^bDescribed in the Treatment of Tuberculosis: Guidelines for National Programmes (The World Health Organization's Stop TB Department).

Supplementary Table 2. Glycemic status of TB cases in RePORT and SINAN (2015-2019) cohorts by drug resistance TB

Glycemic status	Multidrug resistance	Drug-susceptible	p-value
RePORT	n=15	n=721	
Dysglycemia -n (%)	9 (60.0)	402 (55.8)	0.799
Diabetes -n (%)	4 (26.7)	156 (21.6)	0.633
Prediabetes -n (%)	5 (33.3)	246 (34.1)	0.899
Normoglycemia -n (%)	6 (40.0)	319 (44.2)	ref.
SINAN	n=24	n=11159	
Diabetes -n (%)	14 (56.0)	6000 (53.8)	0.823
Normoglycemia -n (%)	11 (44.0)	5159 (46.2)	ref.

Table note: Data represent n. (%). Normoglycemia was used as a reference to calculates p-values of Dysglycemia, diabetes and prediabetes.

Abbreviations: ref.=reference

Supplementary Table 3. Characteristics of patients in RePORT cohort according death and favorable treatment outcome

Characteristics	Death (n=55)	Favorable (n=674)	p-value
Male, n (%)	43 (78.2)	429 (63.6)	0.039
Age, median (IQR)	40 (30-58)	36 (25-49)	0.002
Race, n (%)			0.028
White	10 (18.2)	152 (22.6)	
Black	8 (14.5)	172 (25.6)	
Asian	0 (0)	4 (0.6)	
Pardo	34 (61.8)	336 (49.9)	
Indigenous	3 (5.5)	9 (1.3)	
lliterate, n (%)	52 (94.5)	645 (95.7)	0.727
Smoking, n (%) ^a	37 (67.3)	328 (48.7)	0.011
Alcohol consumption, n (%) ^b	48 (87.3)	550 (81.6)	0.363
Illicit drug use, n (%) ^c	23 (41.8)	180 (26.7)	0.019
Prior TB, n (%)	11 (20.4)	117 (17.5)	0.58
Type of TB, n (%) ^d			1
РТВ	50 (90.9)	604 (89.6)	
PTB+EPTB	5 (9.1)	70 (10.4)	
Abnormal X-ray, n (%)	50 (90.9)	658 (97.6)	0.102
Positive smear, n (%)	45 (83.3)	540 (80.2)	0.722
Resistance, n (%)			<0.001
Isoniazid	7 (14)	33 (5.1)	
Rifampicin	5 (10)	11 (1.7)	
Any Drug ^e	6 (12)	72 (11.2)	
Multidrug ^f	3 (6)	9 (1.4)	
Glycemic status, n (%)	, ,	,	
Diabetes	22 (40)	131 (19.6)	0.005
Prediabetes	13 (23.6)	235 (35.1)	0.719
Normoglycemia	20 (36.4)	303 (45.3)	Ref.
Dysglycemia, n (%)	35 (63.6)	366 (54.7)	0.208
Hemoglobin (g/dL), median (IQR)	9.45 (7.95-10.99)	12.2 (11-13.4)	<0.001
HbA1c (%), median (IQR)	6.2 (5.2-7.1)	5.7 (5.4-6.2)	0.016
HIV status, n (%)	31 (56.4)	102 (15.3)	<0.001
ART, n (%) ^g	8 (25.8)	35 (34)	0.511
Hypertension, n (%)	8 (14.5)	59 (8.8)	0.149
Other comorbidities, n (%) ^h	9 (12.7)	32 (4.9)	0.012

Table Note: Data represent n. (%) or median with Interquartile range (IQR).

Favorable: cure/complete treatment.

^aSmoking: Past or current cigarette smoker. ^bAlcohol consumption: Past or current any consumption of alcohol. ^cIllicit drug use: Past or current illicit drug use (marijuana, cocaine, heroin or crack). ^dAll individuals from the RePORT cohort had a diagnosis of pulmonary tuberculosis, in some cases with presence in other anatomical sites. ^eAny drug (anti-TB) resistance except rifampicin and isoniazid: Pyrazinamide, ethambutol, streptomycin, kanamycin, ethionamide. ^f.Multidrug: TB caused by *Mycobacterium Tuberculosis* strains that are resistant to at least both rifampicin and isoniazid. ^g ART frequency was calculated among the persons living with HIV. ^h It include cancer, kidney disease, chronic obstructive pulmonary disease, emphysema, and asthma.

Abbreviations: TB: Tuberculosis. PTB: Pulmonary TB. EPTB: Extrapulmonary TB. HIV: Human Immunodeficiency Virus. DOT: Directly Observed Therapy. ART: Antiretroviral therapy.

Supplementary Table 4. Characteristics of patients in SINAN cohort according death and favorable treatment outcome


Characteristics	Death (n=111)	Favorable (n=23747)	p-value
Male, n (%)	80 (72.1)	13010 (62.8)	0.050
Age, median (IQR)	48 (35-62)	40 (28-54)	<0.001
Race, n (%)			0.883
White	26 (26.0)	5116 (26.4)	
Black	19 (19.0)	3495 (18.1)	
Asian	2 (2.0)	170 (0.9)	
Pardo	53 (53.0)	10500 (54.3)	
Indigenous	0 (0.0)	62 (0.3)	
Illiterate, n (%)	15 (21.7)	2422 (15.3)	0.134
Smoking, n (%) ^a	28 (31.5)	3540 (18.0)	<0.001
Alcohol consumption, n (%) ^b	22 (25.3)	2600 (13.1)	0.002
Illicit drug use, n (%)°	16 (17.8)	1873 (9.6)	0.018
Prior TB, n (%)	50 (45.0)	3209 (15.5)	<0.001
Type of TB, n (%)			0.185
РТВ	105 (94.6)	20071 (96.8)	
EPTB	1 (0.9)	117 (0.6)	
PTB+EPTB	5 (4.5)	541 (2.6)	
Abnormal X-ray, n (%)	92 (97.9)	17914 (97.3)	1
Positive smear, n (%)	53 (68.8)	10718 (76.3)	0.136
Positive culture, n (%)	29 (85.3)	5877 (71.2)	0.086
Resistance, n (%)			<0.001
Isoniazid	24 (21.6)	76 (0.3)	<0.001
Rifampicin	3 (2.7)	9 (0.03)	<0.001
Any drug ^e	32 (28.8)	145 (55.8)	<0.001
Multidrug ^f	9 (8.1)	13 (0.05)	<0.001
DOT, n (%)	34 (54.8)	10107 (60.6)	0.365
Diabetes, n (%)	18 (18.9)	2066 (10.4)	0.011
HIV infection, n (%)	26 (31.3)	1906 (10.6)	<0.001
ART, n (%) ^g	14 (48.3)	1225 (64.2)	0.001
Hypertension, n (%)	4 (3.6)	567 (2.7)	0.550
Other comorbidities, n (%) ^h	10 (9.6)	804 (4.0)	0.009

Table Note: Data represent n. (%) or median with Interquartile range (IQR).

Favorable: cure treatment outcome

^aSmoking: Past or current cigarette smoker. ^bAlcohol consumption: Past or current any consumption of alcohol. ^cIllicit drug use: Past or current illicit drug use (marijuana, cocaine, heroin, or crack). ^eART frequency was calculated among the persons living with HIV. ^einclude cancer, chronic obstructive pulmonary /emphysema, kidney disease, heart disease, liver disease, depression, dermatitis, and asthma. ^f.Multidrug: TB caused by *Mycobacterium Tuberculosis* strains that are resistant to at least both rifampicin and isoniazid. ^gART frequency was calculated among the persons living with HIV. ^h It include cancer, kidney disease, chronic obstructive pulmonary disease, emphysema, and asthma.


Abbreviations: TB: Tuberculosis. PTB: Pulmonary TB. EPTB: Extrapulmonary TB. HIV: Human Immunodeficiency Virus. DOT: Directly Observed Therapy. ART: Antiretroviral therapy.



Supplementary Figure 1. Frequency of clinical characteristics of TB patients from RePORT-Brazil and SINAN cohorts by treatment outcome

(A)Frequency of symptoms, **(B)** smear positive, abnormal X -ray and HIV infection of TB cases reported cases according to the outcome in RePORT cohort. **(C)** frequency of smear positive, abnormal X -ray and HIV infection of TB cases according to the outcome reported to SINAN between 2010-2014. **(D)** frequency of smear positive, abnormal X -ray and HIV infection of TB cases according to the outcome reported to SINAN between 2015-2019. The data were compared between the groups using the Fisher's exact test (2×2 comparisons). Only comparisons with significant p-values are displayed.

Abbreviations: RePORT: Regional Prospective Observational Research for Tuberculosis. SINAN: Sistema de Informação de Agravos de Notificação (Brazilian National System of Notification of Diseases). TB: Tuberculosis.



Supplementary Figure 2. Frequency of clinical characteristics of TB patients from RePORT-Brazil and SINAN cohorts by glycemic status

(A)Frequency of symptoms, (B) smear positive, abnormal X -ray and HIV infection of TB cases reported cases according to glycemic status (diabetes, prediabetes and normoglycemia) in RePORT cohort. (C) frequency of smear positive, abnormal X -ray and HIV infection of TB cases according to diabetes condition reported to SINAN between 2010-2014. (D) frequency of smear positive, abnormal X -ray and HIV infection of TB cases according to diabetes condition reported to SINAN between 2015-2019. The data were compared between the groups using Chi-square test with Yates correction or Fisher's two-tailed test in 2x3 or 2x2, respectively Only comparisons with significant p-values are displayed.

Abbreviations: RePORT: Regional Prospective Observational Research for Tuberculosis. SINAN: Sistema de Informação de Agravos de Notificação (Brazilian National System of Notification of Diseases). TB: Tuberculosis.